Stuart Schreiber startup launches with $50M to take molecular glue medicines beyond protein degradation

Ryan Cross

Senior Science Correspondent

Magnet Biomedicine launched Tuesday morning with $50 million in Series A financing to expand the scope of molecular glues, drugs that link two proteins together to change their behavior. Founding investor Newpath Partners and ARCH Venture Partners led the round.

Most molecular glue research has focused on compounds that pair a badly behaving protein with a single E3 ligase — a large family of enzymes that tag proteins for degradation. Magnet was founded to develop different kinds of matchmaker molecules.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Stuart Schreiber startup launches with $50M to take molecular glue medicines beyond protein degradation

Ryan Cross

Senior Science Correspondent

Unlock this article instantly by becoming a free subscriber.

New Biosecure draft features 2032 grandfather clause, five-year grace period for added companies

Scientists and startups reveal new gene insertion techniques, though much remains behind closed doors: #ASGCT24

Tessera unveils promising in vivo gene editing treatment for sickle cell in an increasingly competitive field: ...

Across two clinical trials, gene therapy restores hearing in children deaf since birth: #ASGCT24

Lawmakers consider limiting how long existing WuXi contracts can continue

Medical Affairs: The Critical Link Between Science, Physicians and Patients

Stu­art Schreiber start­up launch­es with $50M to take mol­e­c­u­lar glue med­i­cines be­yond pro­tein degra­da­tion

Ryan Cross

Senior Science Correspondent

Unlock this article instantly by becoming a free subscriber.

New Biose­cure draft fea­tures 2032 grand­fa­ther clause, five-year grace pe­ri­od for added com­pa­nies

Sci­en­tists and star­tups re­veal new gene in­ser­tion tech­niques, though much re­mains be­hind closed doors: #AS­GCT24

Tessera un­veils promis­ing in vi­vo gene edit­ing treat­ment for sick­le cell in an in­creas­ing­ly com­pet­i­tive field: ...

Across two clin­i­cal tri­als, gene ther­a­py re­stores hear­ing in chil­dren deaf since birth: #AS­GCT24

Law­mak­ers con­sid­er lim­it­ing how long ex­ist­ing WuXi con­tracts can con­tin­ue

Med­ical Af­fairs: The Crit­i­cal Link Be­tween Sci­ence, Physi­cians and Pa­tients

Stuart Schreiber startup launches with $50M to take molecular glue medicines beyond protein degradation

New Biosecure draft features 2032 grandfather clause, five-year grace period for added companies

Scientists and startups reveal new gene insertion techniques, though much remains behind closed doors: #ASGCT24

Tessera unveils promising in vivo gene editing treatment for sickle cell in an increasingly competitive field: ...

Across two clinical trials, gene therapy restores hearing in children deaf since birth: #ASGCT24

Lawmakers consider limiting how long existing WuXi contracts can continue

Medical Affairs: The Critical Link Between Science, Physicians and Patients